Aug 2026· Immunological Investigations· pp.
1-18
· 0 citations· 19 references
Medicine
TL;DR
Numb participates in coordinating inflammatory and fibrotic responses in IPF and may act as a regulatory mediator in inflammation - fibrosis coupling and may act as a regulatory mediator in inflammation - fibrosis coupling.
Abstract
Background
In idiopathic pulmonary fibrosis (IPF), inflammatory signaling and fibrotic remodeling often coexist, yet the mechanism linking these processes remains unclear. Numb, a cell fate determinant protein, has been implicated in tissue remodeling but its role in inflammation - fibrosis coupling is not well defined.
Methods
Public transcriptomic datasets were analyzed to assess NUMB expression patterns and associated pathways. A bleomycin (BLM)-induced mouse model was used for in vivo validation. In vitro, MRC-5 fibroblasts were stimulated with IL-1β and TGF-β1, alone or in combination, followed by Numb siRNA intervention. Cell viability, migration, cytokine secretion, and fibrosis-related protein expression were evaluated.
Results
Transcriptomic analysis showed a non-significant but consistent upward trend of NUMB in IPF tissues (p = .18), with pathway-level enrichment in inflammatory and extracellular matrix processes. In BLM-treated mice, IL-1β and TGF-β1 levels were significantly increased (both p < .001), accompanied by upregulation of Numb (p < .05), α-SMA, and Collagen I (both p < .001). In vitro, IL-1β and TGF-β1 synergistically enhanced cell viability and migration (both p < .001), as well as protein expression (p < .001). Numb silencing reduced cytokine secretion (p < .001), cell activation (p < .05-0.001), and fibrosis-related protein expression (p < .001).
Conclusion
Numb participates in coordinating inflammatory and fibrotic responses in IPF and may act as a regulatory mediator in inflammation - fibrosis coupling.
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal interstitial lung disease characterized by aberrant profibrotic signaling and excessive extracellular matrix deposition, accompanied by fibroblast-to-myofibroblast transition. Despite extensive investigation, the molecular mechanisms underlying IPF pathogen...
Jiawei Chen, Yu Li, Kai Fu et al.· Cellular Signalling· 0 citations
Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease driven by fibroblast activation and extracellular matrix deposition. Endothelial-to-mesenchymal transition (EndMT) critically contributes to vascular injury and fibrotic remodeling in IPF. Legumain (LGMN), a lysosomal cysteine protease involved in...
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease (ILD) of unclear etiology. Dupilumab, a humanized monoclonal antibody binding to interleukin-4 receptor alpha (IL-4Rα), suppresses both IL-4 and IL-13 signaling pathways. However, the therapeutic potential in IPF is unclear. This re...
Qi Chen, Yu-Pei Zhang, Shi-Yang Wang et al.· Lung· 0 citations
Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by aberrant fibroblast activation and excessive extracellular matrix accumulation, predominantly collagen, leading to irreversible lung remodeling. Sinigrin (SNG), a naturally occurring glucosinolate with reported anti-inflam...
Suriya Panneerselvam, J. S, Anoop Kishore et al.· ACS Pharmacology & Trans...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.